Trinity buys Selfcare subsidiary:
This article was originally published in Clinica
Trinity Biotech is to acquire the infectious diseases testing business of Cambridge Diagnostics Ireland, a subsidiary of Waltham, Massachusetts-based Selfcare. Trinity is paying for the deal with around 500,000 shares in Selfcare (which it owned) plus $280,000 in cash. Cambridge had revenue last year of $3.2 million. Its products include three tests for HIV antibodies. Capillus HIV and RTD HIV are rapid doctors' office-based tests, while Recombigen is a microtitre test for laboratories and blood tests.